Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 1/20 | 0.52 |
| ▸ | F3 | P13726 | 1/20 | 0.52 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.52 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.52 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.52 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.52 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
| ▸ | PLOD2 | O00469 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL283481 | 0.82 | HDAC1 (0.60) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL15588644 | 0.81 | F7 (0.53) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL14595304 | 0.80 | ALDH1A1 (0.52) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL8481624 | 0.79 | ALDH1A1 (0.56) | F7F3SARM1SIRT2SIRT6 | |
| Hydrochloric Acid SCHEMBL8485517 | 0.78 | ALDH1A1 (0.54) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL16791193 | 0.77 | ALDH1A1 (0.49) | F7F3SARM1SIRT2SIRT6 | |
| SCHEMBL31404951 | 0.77 | — | — | |
| SCHEMBL415017 | 0.77 | — | — | |
| Nicotinic Acid Hydrazide SCHEMBL258390 | 0.76 | HDAC1 (0.69) | F7F3SARM1SIRT2SIRT6 | |
| Nicotinic Acid Hydrazide SCHEMBL29648965 | 0.76 | HDAC1 (0.69) | F7F3SARM1SIRT2SIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016120432-A1 | COMPOUNDS AND METHODS FOR ANTICOAGULATION THERAPY | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2016-08-04 | — | — | WO | disclosed |
| US-20080096894-A1 | Anti-Bacterial Compounds | ASTON UNIVERSITY (GB) | 2008-04-24 | — | — | US | disclosed |
| EP-1845779-A1 | ANTI-BACTERIAL COMPOUNDS | Aston University (GB) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006075159-A1 | ANTI-BACTERIAL COMPOUNDS | ASTON UNIVERSITY (GB) | 2006-07-20 | — | — | WO | disclosed |
| JP-2004083415-A | NICOTINAMIDRAZONE DERIVATIVE | SANKYO AGRO KK | 2004-03-18 | — | — | JP | disclosed |
| WO-2004005291-A1 | HETERO-CYCLICALY SUBSTITUTED IMIDAZOTRIAZINES | BAYER HEALTHCARE AG (DE) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096894-A1 | Anti-Bacterial Compounds | MRPL21, PGLS, FOSB | F7 1015/4885F3 1908/4885SARM1 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.